503 related articles for article (PubMed ID: 23830148)
1. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity.
Katsidoni V; Kastellakis A; Panagis G
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2273-84. PubMed ID: 23830148
[TBL] [Abstract][Full Text] [Related]
2. Lack of evidence for appetitive effects of Delta 9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents.
Vlachou S; Nomikos GG; Stephens DN; Panagis G
Behav Pharmacol; 2007 Jul; 18(4):311-9. PubMed ID: 17551324
[TBL] [Abstract][Full Text] [Related]
3. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
4. Delta(9)-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: involvement of cannabinoid CB(1) receptor and serotonergic system.
Egashira N; Matsuda T; Koushi E; Higashihara F; Mishima K; Chidori S; Hasebe N; Iwasaki K; Nishimura R; Oishi R; Fujiwara M
Eur J Pharmacol; 2008 Jul; 589(1-3):117-21. PubMed ID: 18565508
[TBL] [Abstract][Full Text] [Related]
5. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
6. Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.
Wiebelhaus JM; Grim TW; Owens RA; Lazenka MF; Sim-Selley LJ; Abdullah RA; Niphakis MJ; Vann RE; Cravatt BF; Wiley JL; Negus SS; Lichtman AH
J Pharmacol Exp Ther; 2015 Feb; 352(2):195-207. PubMed ID: 25398241
[TBL] [Abstract][Full Text] [Related]
7. Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184.
Feliszek M; Bindila L; Lutz B; Zimmer A; Bilkei-Gorzo A; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):603-12. PubMed ID: 26984820
[TBL] [Abstract][Full Text] [Related]
8. CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat.
Vlachou S; Nomikos GG; Panagis G
Psychopharmacology (Berl); 2005 May; 179(2):498-508. PubMed ID: 15821959
[TBL] [Abstract][Full Text] [Related]
9. Effects of delta9-tetrahydrocannabinol on reward and anxiety in rats exposed to chronic unpredictable stress.
Fokos S; Panagis G
J Psychopharmacol; 2010 May; 24(5):767-77. PubMed ID: 19406854
[TBL] [Abstract][Full Text] [Related]
10. Effects of endocannabinoid neurotransmission modulators on brain stimulation reward.
Vlachou S; Nomikos GG; Panagis G
Psychopharmacology (Berl); 2006 Oct; 188(3):293-305. PubMed ID: 16953388
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat.
Freedland CS; Whitlow CT; Miller MD; Porrino LJ
Synapse; 2002 Aug; 45(2):134-42. PubMed ID: 12112406
[TBL] [Abstract][Full Text] [Related]
12. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
Stewart JL; McMahon LR
J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
[TBL] [Abstract][Full Text] [Related]
13. Dissociable effects of the cannabinoid receptor agonists Δ9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats.
Kwilasz AJ; Negus SS
J Pharmacol Exp Ther; 2012 Nov; 343(2):389-400. PubMed ID: 22892341
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine.
Vlachou S; Stamatopoulou F; Nomikos GG; Panagis G
Int J Neuropsychopharmacol; 2008 Nov; 11(7):905-23. PubMed ID: 18377702
[TBL] [Abstract][Full Text] [Related]
15. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.
Cox ML; Haller VL; Welch SP
Eur J Pharmacol; 2007 Sep; 570(1-3):50-6. PubMed ID: 17588560
[TBL] [Abstract][Full Text] [Related]
16. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
Darmani NA
Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
[TBL] [Abstract][Full Text] [Related]
17. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
[TBL] [Abstract][Full Text] [Related]
18. Facilitation of brain stimulation reward by delta 9-tetrahydrocannabinol.
Gardner EL; Paredes W; Smith D; Donner A; Milling C; Cohen D; Morrison D
Psychopharmacology (Berl); 1988; 96(1):142-4. PubMed ID: 2852376
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
Booker L; Naidu PS; Razdan RK; Mahadevan A; Lichtman AH
Drug Alcohol Depend; 2009 Nov; 105(1-2):42-7. PubMed ID: 19679411
[TBL] [Abstract][Full Text] [Related]
20. CB1 receptor stimulation in specific brain areas differently modulate anxiety-related behaviour.
Rubino T; Guidali C; Vigano D; Realini N; Valenti M; Massi P; Parolaro D
Neuropharmacology; 2008 Jan; 54(1):151-60. PubMed ID: 17692344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
